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Background: In recent years anti-TNF therapy has been associated with leishmaniasis in immunocompromised
patients from endemic areas. Nevertheless, data on asymptomatic Leishmania infection in such patients is scarce.
The aim of this study was to determine the prevalence of asymptomatic infection in inflammatory bowel disease
(IBD) patients treated with TNF inhibitors living in an endemic area (Catalonia) and to follow up them to study
how the infection evolved.
Methods: 192 IBD patients (143 Crohn's disease; 49 ulcerative colitis) from Catalonia (Spain), an area endemic for
L. infantum, were recruited. Peripheral blood samples were collected and tested for anti-Leishmania antibodies by
Western blotting (WB). Leishmania kinetoplast DNA was detected in peripheral blood mononuclear cells (PBMC)
by a quantitative PCR.
Results: Serology was positive in 3.1% and Leishmania DNA was found in 8.8%, with a low parasitic load and
humoral response. The prevalence was 10.9%, patients being considered infected if they tested positive by at least
one of the techniques. Eight out of the 21 patients with asymptomatic leishmaniasis were monitored for 3–8
months after the first test. None of them showed an increased parasitemia or humoral response, or developed
leishmaniasis during the follow-up period.
Conclusion: The prevalence of Leishmania asymptomatic infection detected in our IBD cohort is similar to that
found in healthy population in close endemic areas. Due to the short monitoring period, it is not possible to reach
a conclusion about the risk of Leishmania reactivation from this study.1. Introduction
Leishmaniasis is a vector-borne infectious disease caused by obligate
intracellular parasites of the genus Leishmania. Three main clinical forms
can be differentiated, visceral (VL), cutaneous (CL) and mucocutaneous,
which develop according to the Leishmania species, strain virulence and
host immune response. Leishmania infantum is endemic in the Mediter-
ranean basin and causes cutaneous and visceral disease. It is well
established that in this area there is a natural exposure to the parasite and
asymptomatic Leishmania infection is present (Riera et al., 2008; Le
Fichoux et al., 1999).Whereas most immunocompetent individuals willm 12 December 2019; Accepted
evier Ltd. This is an open access anot develop the disease after Leishmania infection, immunosuppression is
a recognized risk factor that may lead to either reactivation of a latent
infection or failure to control a new infection. It can also alter the disease
symptoms and the response to treatment (Van Griensven et al., 2014).
In recent years the number of reported cases of leishmaniasis in pa-
tients being treated with anti-TNF in endemic areas has increased, which
suggests a possible heightened risk of developing VL or CL (Zanger and
Gabrysch, 2013; Catala et al., 2015). The development of unusually large
and persistent cutaneous lesions and even visceralization of Leishmania in
IBD patients treated with TNF inhibitors or immunossupressant therapy
has also been described (Marcoval et al., 2017; Delgado et al., 2017).4 May 2020
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biological drugs is scarce.
The aim of this study was to determine the prevalence of asymp-
tomatic infection in such patients living in an endemic area (Catalonia)
and to follow up asymptomatic infected patients to study how the
infection evolved.
2. Material and methods
2.1. Patients: demographic characteristics and treatment
In a cross sectional study, 192 IBD patients being treated with TNF
inhibitors and living mostly in urban and peri-urban areas of Barcelona
(Catalonia) were recruited at the Crohn's and Colitis Attention Unit in
Vall d’Hebron University Hospital from April to October 2016 (143 pa-
tients with Crohn's disease (CD) and 49 with ulcerative colitis (UC)). The
criteria for inclusion in this study were that they were adults of over 18
years, of either gender, and did not present any of the characteristic
symptoms of leishmaniasis. All patients gave their written informed
consent to participate in the study that was approved by the Ethics
Committee of the Vall d’Hebron University Hospital. Epidemiological
and clinical data were recorded in a clinical interview. The study was
conducted according to the tenets of the Declaration of Helsinki. Out of
the total, 180 patients had been previously treated or were being treated
with different immunosuppresive drugs, including Azathioprine, Myco-
phenolate, Methotrexate, 6-Mercaptopurine, Sirolimus and Cyclosporin,
and only 12 had never been treated with immunosupressants prior to
anti-TNF therapy. Demographic and treatment data about the patients
are summarized in Table 1.
2.2. Antibody detection and PCR procedure
Peripheral blood samples were obtained by sterile venipuncture and
the serum was separated by centrifugation and tested for anti-Leishmania
antibodies by Western blotting (WB) using a whole L. infantum antigen
(MHOM/FR/78/LEM 75 zymodeme MON-1) according to Riera et al
(Riera et al. (1999). The WB assay was performed on 0.1% sodium
dodecyl sulfate-13% polyacrylamide gel on a mini-gel system (Bio-Rad).Table 1. Demographic characteristics and treatment of IBD patients studied. Non-inf
Patients' characteristics n ¼ 192 Non-infected patients n ¼ 171 Asympto
Total Pos
Age (years) 18-74 (Mdn 41) 20-68 (M
Gender (Male/Female) 84/87 8/13
Dog's ownership (%) 50% 48%
Type of IBD
 CD 132 (77%) 14 (67%
 UC 39 (23%) 7 (33%)
Biological Drugs
 IFX 85 (50%) 10 (48%
 ADA 80 (47%) 9 (43%)
 GLM 6 (3%) 2 (9%)
Time on BD 1-180 (Mdn 53) 8-144 (M
Concomitant IST
 AZA 97 (57%) 10 (48%
 6-MP 17 (10%) 1 (4%)
 MTX 3 (2%) -
 AZA þ MTX 2 (1%) -
 6-MP þ Sirolimus 2 (1%) -
No conc. IST 50 (29%) 10 (48%
* Patients with at least one positive test were considered to be infected. Mdn: Media
Colitis. IFX: Infliximab, ADA: Adalimumab, GLM: Golimumab. BD: Biological drug.
immunosuppressant therapy. AZA: Azathioprine, 6-MP: 6-Mercaptopurine, MTX: Met
2
Serum samples were diluted at 1/50, were assayed and a purified form of
Pierce™ Protein A (Thermo Scientific) peroxidase conjugate (1/1000
dilution) was used. A molecular weight marker (BioRad) was used.
Immunoreactivity against 14 and/or 16 kDa L. infantum specific antigen
fractions was considered a positive result. Leishmania kinetoplast DNA
was detected in peripheral blood mononuclear cells (PBMC obtained
from 10 mL of EDTA-anticoagulated blood by density gradient centrifu-
gation over Ficoll-Paque) by a quantitative PCR (qPCR) (Mary et al.,
2004: Molina et al., 2013). Each amplification was performed in tripli-
cate in a 20 μL reaction mixture containing 1 x iTaq supermix with Rox,
15 pmol direct primer (CTTTTCTGGTCCTCCGGGTAGG), 15 pmol
reverse primer (CCACCCGGCCCTATTTTACACCAA), 50 pmol labeled
TaqMan probe (FAM-TTTTCGCAGAACGCCCCTACCCGC-TAMRA), and 5
μL sample DNA. A non-template control was included in each run as the
PCR negative control. Results were expressed as parasite equivalents per
ml of blood (p.e./ml), considering values 0.001 p.e./ml (threshold
cycle tC < 40) as positive (Mary et al., 2006).
A 10-fold dilution series of standard DNA from promastigotes
(MHOM/ES/04/BCN-61; L. infantum ZMON-1) was used as a calibrator
(serial dilution from 105 parasites/mL to 103 parasites/mL), allowing
for the plotting of a standard curve.
Patients with at least one positive test were considered infected and
underwent further monitoring; a second blood sample was obtained and
serology and qPCR was performed. The differences in characteristics
between infected and non-infected patients were determined using
Fisher's test.
3. Results
Six out of 192 patients had positive serology results, showing
immunoreactivity against 14 and/or 16 kDa antigen fractions (3.1%
[95%CI 1.3–6.8%]). 171 patients out of the total could be tested by PCR.
Parasite DNA was detected in 15 out of the 171 patients (8.8% [95% CI
5.3–14.1%]), even in the absence of a humoral response. Parasite load
ranged between 0.001 and 1 p.e./ml as follows: 1 p.e./ml in one patient,
0.1 p.e./ml in another patient, 0.01 p.e./ml in four patients and 0.001
p.e./ml in nine patients. Twenty-one out of the 192 patients (10.9% [95%
CI 7.2–16.2%]) tested positive by at least one of the assayed techniquesected and asymptomatic infected patients according to qPCR and WB results.
matic infected patients* n ¼ 21
itive Patients (n ¼ 21) Positive qPCR (n ¼ 15) Positive WB (n ¼ 6)
dn 40) 20-68 (Mdn 38.5) 28-68 (Mdn 48)
6/9 2/4
40% 67%
) 9 (60%) 5 (83%)
6 (40%) 1 (17%)
) 6 (40%) 4 (67%)
7 (47%) 2 (33%)
2 (13%) -
dn 47) 8-84 (Mdn 38.5) 18-144 (Mdn 68)





) 8 (53%) 2 (33%)
n. IBD: Type of inflammatory bowell disease. CD: Crohn's Disease. UC: Ulcerative
Time on BD: Time on biological treatment in months. Conc. IST: Concomitant
hotrexate.
Table 2. Serological and molecular results of asymptomatic infected patients in the first and the second assessment.
Patient First assessment Second assessment Follow-up
WBa qPCRb WBa qPCR
1 Neg 0.1 Neg Neg 7
2 14, 16 Neg 14, 16 Neg 7
3 14, 16 Neg 14 Neg 7
4 14, 16 Neg Neg Neg 8
5 14, 16 Neg 14 Neg 7
6 Neg 1 Neg Neg 3
7 14, 16 Neg Neg Neg 4
8 16 Neg 14 Neg 3
Follow-up: Months between the 1st and the 2nd blood test. WB: Western Blot.
a L. infantum antigen fractions (kD).
b Positive results by qPCR are expressed as parasite equivalent/ml.
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clinical symptoms of active leishmaniasis.
Eight of the 21 positive patients were followed up and a second blood
sample was collected between 3 and 8 months after the first test. Follow-
up by qPCR was possible in the two patients with parasitemia between
0.1 and 1 p.e./ml. These results are shown in Table 2.
No statistically significant differences were found between the two
groups of IBD patients (infected and non-infected) (Table 1) according to
gender distribution, age or dog ownership, nor any association between
infection and the type of IBD or the administered treatment (biological
drugs/immunosuppressant therapy) (p > 0.05).
4. Discussion
Leishmania asymptomatic infection has been reported in healthy
population living in Mediterranean endemic areas (Riera et al., 2008; Le
Fichoux et al., 1999; Sakru et al., 2007). However, the prevalence of
asymptomatic leishmaniasis in anti-TNF-treated IBD patients in these
areas is unknown. In the absence of a gold standard to measure asymp-
tomatic infection, it is hard to know whether these seropositive in-
dividuals who remained healthy were truly infected with Leishmania.
Techniques such as WB and PCR are considered able to detect cryptic
infection, in addition to others such as the skin test and cell-mediated
immune response (Riera et al., 2008; Ibarra-Meneses et al., 2016; Car-
rillo et al., 2015).
To our knowledge, the present study is the first asymptomatic Leish-
mania infection survey in IBD patients receiving biological drugs. Herein,
a significant proportion of IBD patients had positive results for Leishmania
by WB and/or qPCR, with a low and intermittent parasitic load and low
humoral response, which is characteristic of asymptomatic infection
(Riera et al., 2008; Le Fichoux et al., 1999; Mary et al., 2006). Some
studies point out that the presence of antibodies does not always come
with a positive PCR in asymptomatic population (Ortalli et al., 2019).
This absence of correlation between serological and molecular methods
may be explained by a previous resolved infection by Leishmania which
would show anti-Leishmania antibodies but would not detect DNA.
Leishmaniasis is of public health significance and a notifiable disease
in Spain. The zones of Spain with the highest incidence rate of leish-
maniasis are Catalonia, the Balearic Islands, Madrid, Valencia and the
Mediterranean areas of Andalusia. According to the official data
(www.isciii.es. Enfermedades EDO, 2017), the overall rate of leishman-
iasis in Catalonia was 0.82 cases/100.000 inhabitants in 2017 but the
prevalence of asymptomatic infection in this area is unknown.
Although it is difficult to distinguish between a new and a latent
infection in patients living in an endemic area, the prevalence detected
was similar to that reported in other studies on healthy individuals from
close endemic areas in Spain and in other endemic Mediterranean
countries (Riera et al., 2008; Le Fichoux et al., 1999; Sakru et al., 2007;3
Tordini et al., 2011; Perez-Cutillas et al., 2015; Jimenez-Marco et al.,
2016; Maritati et al., 2018).
The main limitations of our study were the difficulty of monitoring all
cryptically infected patients and the short duration of the follow-up
period since only 8 patients with asymptomatic leishmaniasis were fol-
lowed up and for a short period of time. During the monitoring period
none of our patients showed an increased parasitemia or humoral
response, or any reactivation. On the contrary, they became negative or
maintained the low results.
In our study, no associations were found between infection and
demographical and clinical characteristics. Administered biological
medication did not appear to influence infection.
There is controversy about the usefulness of conducting studies to
detect the infection status in such patients. Some authors suggest that
exposure to Leishmania should be determined in patients who need to be
kept in an immunosuppressed state (Carrillo et al., 2015). Others
recommend serological and molecular screening before initiating
anti-TNF therapy (Marcoval et al., 2017; Maritati et al., 2018). In
contrast, ECCO Guidelines (Rahier et al., 2014) do not support a general
policy of screening for parasitic infections prior to initiating biological
treatment, with certain exceptions, such as Strongyloides stercoralis.
Due to the lack of information on subclinical infection in such pa-
tients, Zanger et al. (Zanger and Gabrysch, 2013) stress the importance of
providing prospective data from a well-defined population to be able to
estimate the incidence of clinical infection due to anti-TNF use. Studies
like ours carried out on IBD patients and others on patients with rheu-
matic diseases (Maritati et al., 2018) provide information on the preva-
lence of Leishmania subclinical infection in these specific patients treated
with anti-TNF in endemic areas.
5. Conclusions
The prevalence found was similar to that reported in other studies
on healthy individuals from close endemic areas. It is not possible to
reach a conclusion about the risk of Leishmania reactivation from this
study due to the short monitoring period. A more complete and longer
follow-up would have strengthened our results and would have pro-
vided more information about how the infection evolves and if the risk
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